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Ionizing radiation of specifically targeted cells in a given population is known to elicit pro-death or pro-survival 
responses in non-targeted bystander cells, which often make no physical contact with the targeted ones. We have 
recently demonstrated a similar phenomenon for non-ionizing photodynamic therapy (PDT), showing that 
prostate cancer cells subjected to targeted photodynamic stress stimulated growth and migration of 
non-stressed, non-contacting bystander cells. Diffusible nitric oxide (NO) generated by stress-upregulated 
inducible nitric oxide synthase (iNOS) was shown to play a dominant role in these responses. Moreover, 
target-derived NO stimulated iNOS/NO induction in bystanders, suggesting a NO-mediated feed-forward field 
effect driven by targeted cells surviving the photodynamic challenge. In this research highlight, we will review 
these findings and discuss their potential negative implications on clinical PDT outcomes and how these might be 
mitigated through pharmacologic use of select iNOS inhibitors.   
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Brief background on nitric oxide and its role in cancer 
Nitric oxide (NO) is a short-lived bioactive free radical 
that diffuses freely on its own and, like oxygen (O2), tends to 
partition into hydrophobic regions of cells, e.g. cell 
membranes [1-3]. NO at low to moderate steady state levels, 
e.g. 50-500 nM, is known to play a key signaling role in the 
survival, proliferation, migration, and drug-resistance of 
many cancer cell types [3-5]. By contrast, NO at relatively 
high levels (>1 µM), as generated by activated macrophages, 
for example, is cytotoxic, particularly after conversion to the 
strong oxidant peroxynitrite [1, 2]. Thus, whether NO exhibits 
pro-tumor vs. anti-tumor properties depends to a great extent 
on the steady state levels that it can attain, which are 
typically quite low in transformed cells, as mentioned. While 
naturally occurring NO is known to be generated by three 
different nitric oxide synthases in mammalian cells (NOS1, 
NOS2, NOS3), NOS2 or inducible NOS (iNOS) is the 
isoform most closely associated with cancer initiation, 
progression, and persistence [4-8]. Depending on a number of 
variables, many cancer cells, including those derived from 
breast, prostate, colon, and brain tumors, express significant 
constitutive levels of iNOS/NO, which are often implicated 
in pro-survival/pro-growth signaling [4-6]. Knockdown of 
pre-existing iNOS using siRNA or shRNA methodology has 
been shown to attenuate growth and progression of various 
tumors in animal models [4-6], thereby substantiating 
iNOS/NO’s tumor-supporting role. iNOS level in resected 
tumors from cancer patients is now considered a reliable 
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prognostic indicator, patients with highest levels given the 
poorest survival chances [9, 10]. Although pre-existing iNOS 
may provide a survival/growth advantage in many tumors, 
the level of NO produced may still be limiting. One approach 
for examining this is to determine whether low dose NO 
from an exogenous chemical donor might further stimulate 
cancer cell growth or resistance to therapeutic 
agents/treatments. As one early example, we showed that the 
NO donor spermine-NONOate (SPNO) in sub-toxic doses 
dramatically increased the resistance of human breast cancer 
COH-BR1 cells to photodynamic cell killing [11]. Each of the 
following were shown to contribute to this response: (i) 
suppression of pro-apoptotic JNK and p38α activation, (ii) 
suppression of pro-apoptotic Bax and Bid expression, and 
(iii) suppression of anti-apoptotic Bcl-xL down-regulation 
[11]. 
Photodynamic therapy and how it is affected by NO 
Photodynamic therapy (PDT) is a unique, minimally 
invasive modality for solid tumors that involves a 
photosensitizing agent (PS), PS-exciting light in the far 
visible-to-near infrared range, and molecular oxygen [12-14]. 
Unlike chemotherapy or radiotherapy, PDT has few (if any) 
light-independent PS side effects, i.e. treatment is usually 
limited to the tumor site at which the PS accumulates and at 
which light is applied, often via fiber optic networks. PDT 
photodynamic action gives rise to singlet oxygen (1O2) 
and/or other cytotoxic reactive oxygen species [12-14]. In 1996, 
the first PS to receive FDA approval for certain tumors (e.g. 
esophageal) was Photofrin®, an oligomeric form of 
hematoporphyrin [12]. Since then, it has been used for many 
other malignancies, including bladder, prostate, breast, and 
brain, some of which are resistant to other treatments [13,14]. 
The first in vivo studies to assess whether endogenous NO 
might affect PDT efficacy were carried out using Photofrin® 
as PS and mice bearing various syngeneic tumors [15.16]. The 
key finding was that PDT cure rate could be significantly 
improved by administering a NOS inhibitor immediately 
before [15] or after [16] PDT. Extent of improvement correlated 
with constitutive NO output, tumors with the highest output 
responding best to NOS inhibition [16]. The explanation 
offered was that dilation of tumor-supporting blood vessels 
was acting in opposition to PDT’s vasoconstrictive effects, 
and NOS inhibition relieved this opposition [15, 16]. A similar 
explanation was offered in a more recent study by other 
investigators [17]. 
In addition to pre-existing PSs like Photofrin®, pro-PSs 
have been developed, the most widely used one being 
5-aminolevulinic acid (ALA).  ALA enters tumor cells and 
is metabolized to protoporphyrin IX (PpIX), the active PS, 
via the heme biosynthetic pathway, the PpIX accumulating 
initially in mitochondria [18]. An important feature of 
ALA-PDT is that PpIX tends to accumulate preferentially in 
tumor cells rather than surrounding vascular cells [18, 19]. 
Using this approach, we asked whether NO might antagonize 
PDT not only by vasodilation [15, 16], but also by enhancing 
stress resistance in tumor cells per se. Using human breast 
cancer COH-BR1 cells as an early test system (see above), 
we found that apoptotic photokilling after an ALA-PDT-like 
challenge was strongly inhibited by the exogenous NO donor 
SPNO [11]. Of greater importance vis-à-vis PDT efficacy was 
our subsequent discovery that photodynamic stress itself 
resulted in iNOS upregulation in these cells and that this 
increased their resistance to apoptotic photokilling [20, 21]. We 
found, for example, that after a moderate ALA/light-imposed 
stress, iNOS mRNA was upregulated ~2-fold and iNOS 
protein 3-4-fold, beginning ~2 h after irradiation and 
persisting for at least another 24 h [20, 21]. No changes were 
observed in dark (ALA-only) or light-only controls. nNOS 
and eNOS levels were barely detectable in COH-BR1 cells 
and did not change after ALA/light exposure. Using the 
fluorescent probe DAF-2DA, we found that the level of 
endogenous NO also increased after ALA/light and that 
targeting iNOS with specific inhibitors (1400W, GW274150) 
or intercepting NO with a well-known scavenger (cPTIO) 
strongly attenuated this increase [20]. Moreover, when any 
one of these agents was present during and after a 
photochallenge, the extent of caspase-9 activation and 
apoptosis was substantially greater than in their absence. 
This was also observed when cells with shRNA-induced 
iNOS knockdown were challenged and in this case the effect 
was completely reversed by SPNO-derived NO [20]. 
Collectively, these findings indicated that NO from basal 
and/or photostress-induced iNOS was signaling for increased 
resistance as a stress adaptation. In examining this stress 
signaling from a mechanistic perspective, we found that Akt 
(PI3K-dependent protein kinase B) was rapidly 
phosphorylation-activated by ALA/light, and a PI3K 
inhibitor suppressed this along with transcription factor 
NF-κB activation and iNOS upregulation [21]. These and 
related findings suggested the following course of events: 
photostress activation of Akt, followed by NF-κB activation, 
iNOS transcription/translation, NO upregulation, and 
apoptosis resistance [21]. The signaling mechanism(s) by 
which NO elicits greater resistance are currently under 
investigation. 
Of related interest was our discovery that cancer cells 
which could withstand a photodynamic challenge typically 
exhibited a more aggressive phenotype than unchallenged 
controls in terms of accelerated proliferation, migration, and 
invasion over at least a 48 h post-irradiation period. These 
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responses were observed for prostate PC3 and DU145 cells 
[22, 23], breast MDA-MB-231 cells [24], and glioblastoma U87 
and U251 cells [25]. Similarly to photostress-induced 
resistance, more rapid proliferation and migration/invasion of 
surviving cells was strongly enhanced by 1400W or cPTIO, 
indicating that iNOS/NO also played a major role in these 
responses [22-25]. It is important to note that PC3 cells 
consistently showed the lowest basal level of iNOS and the 
greatest upregulation (10-12-fold) after ALA/light. For these 
cells, therefore, most of the hyper-resistance and 
aggressiveness was due to stress-induced iNOS as opposed to 
pre-existing enzyme. Indeed, for all cells mentioned above, 
the effects described were at least partially due to iNOS 
upregulation. This was the first recognition that iNOS/NO 
induced by an oxidative stress-based anti-cancer therapy 
could antagonize the treatment outcome in multiple ways 
[22-25]. 
Some of the above findings were recently validated at the 
in vivo level by showing that (i) ALA-PDT regression of 
human breast MDA-MB-231 tumor xenografts in 
immunodeficient (SCID) mice was significantly enhanced by 
iNOS inhibitors (1400W, GW274150) and (ii) iNOS protein 
and NO (as nitrite) levels in these tumors were strongly 
elevated over several days after PDT treatment [24]. This was 
the first known evidence for iNOS/NO-induced resistance to 
PDT in an in vivo human tumor model.    
Bystander effects in anti-cancer therapies: role of 
iNOS/NO 
We recently discovered another NO-mediated response to 
PDT-induced oxidative stress, namely stimulation of 
non-stressed bystander cells. In general terms, a bystander 
effect occurs when cells exposed to a stress-inducing 
physical or chemical agent send signals to non- or minimally 
exposed counterparts (bystanders) [26]. Most of the research 
in this area has involved cancer-initiating vs. -suppressing 
ionizing radiation, which can elicit effects ranging from 
DNA damage, mutations, and apoptotic cell death to 
increased growth and migration [27-29]. Radiation-induced 
bystander effects can be transmitted via inter-cell 
gap-junctions or via the medium without physical contact 
between cells [29, 30]. Although a variety of signaling effectors 
have been proposed, including cytokines, H2O2, and NO, the 
latter has received greatest attention for contact-independent 
radiation-induced bystander effects [31-34]. NO from 
radiation-targeted cells has been reported to elicit bystander 
responses ranging from increased proliferation to defective 
homologous recombination repair, the latter promoting 
genetic instability and cell transformation [35]. 
The possibility of bystander effects in conjunction with 
PDT has been recognized for several years [36-38], but far less 
Figure 1. Effect of siRNA-induced iNOS knockdown in target 
cells on bystander cell proliferation. Prostate cancer PC3 cells 
were used, the targeted ones being dark-incubated with 1 mM ALA 
for 30 min in serum-free medium. After irradiation (light fluence ~1 
J/cm2), cells were washed free of ALA and switched to 
serum-containing medium, after which the separating rings were 
removed. Bystander cell proliferation was then monitored over 48 h 
of dark incubation, cell counts being obtained by Image-J analysis of 
photomicrographs. Data from iNOS-kd cells and scrambled vector 
controls (Scr) are compared; values are means ± SEM (n=12). 
*P<0.005 vs. Scr; *P<0.002 vs. Scr. Adapted from Figure 9 in Ref. 
39.     
 
Figure 2. Schematic depicting bystander cell responses to NO 
generated by photodynamically stressed target cells. Both 
populations are irradiated, but only target cells sensitized with 
ALA-induced PpIX in mitochondria experience 1O2-mediated 
oxidative stress leading to iNOS/NO upregulation. The NO increases 
target cell resistance to apoptosis and surviving cells, as well as 
NO-stimulated bystanders, grow and migrate more aggressively. 
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is known about this in mechanistic terms than for the 
radiation-induced counterpart. In addressing this question 
and the possible role of PDT-induced NO, we hypothesized 
that not all cells in a given tumor would be accessed 
uniformly by a PS (or pro-PS like ALA), largely due to 
irregularities in the supporting microvascular system. 
Moreover, not all tumor cells would be uniformly reached by 
subsequent irradiation. Consequently, cells experiencing the 
greatest photodynamic (PS/light) stress might send signals to 
non- or weakly-stressed bystanders. We used a novel 
approach to test this hypothesis and the possibility of NO 
acting as a signaling intermediate [39]. In initial studies, two 
populations of PC3 cells on a large (13.5 cm) culture dish 
were separated by 2-3 impermeable silicone rings; the larger 
population (target cells) was exposed to ALA/light, the other 
(bystander cells within rings) to light alone. At some interval 
after irradiation (typically 2 h), the rings were removed, 
leaving a gap between both populations which was not 
breached during subsequent dark incubation. Both cell 
populations were then analyzed for various post-irradiation 
responses. As expected, target cells displayed a progressive 
and prolonged upregulation of Western-detected iNOS and 
DAF-2-detected NO [39]. More interestingly, we observed a 
slower, yet substantial induction of both iNOS and NO in 
bystander cells. These responses were strongly inhibited by 
cPTIO, indicating a significant dependency on NO initially 
generated in target cells. In addition to iNOS/NO 
upregulation, we observed a striking spurt in bystander 
proliferation and migration, which was forestalled by 1400W 
and cPTIO, implying involvement of iNOS-derived NO [39]. 
When siRNA was used to knock down iNOS in target PC3 
cells, the post-ALA/light bystander growth spurt was 
substantially diminished (Figure 1), confirming that target 
cell iNOS/NO played a major (in not exclusive) role in the 
enhanced aggressiveness [39]. Similar results were obtained in 
breast cancer COH-BR1 target/bystander experiments, 
suggesting general applicability. The lifetime of NO in 
aqueous media is very short, i.e. in the order of a few 
seconds [40]. Incubation with conditioned medium from 
ALA/light-targeted cells did not affect bystander growth rate, 
thereby ruling out any involvement of long-lived (relative to 
NO) effectors in the bystander responses. This includes 
relatively stable byproducts of NO such as nitrite (NO2-) and 
nitrous anhydride (N2O3). Examination of possible effector 
proteins associated with greater growth/migration 
aggressiveness of bystander PC3 cells revealed a strong, yet 
transient, activation of the Akt and ERK1/2 kinases and an 
induction of cyclooxygenase-2 (COX-2), each response 
being cPTIO-inhibitable [39]. Figure 2 is a summary scheme 
showing the targeted photochallenge used in our experiments 
and its NO-mediated effects on bystander cells. In ongoing 
studies, several key issues are being addressed, including (i) 
mechanism(s) of bystander iNOS induction by NO from 
targeted cells, and (ii) mechanisms by which bystander 
growth and migration are stimulated by NO.  
Conclusions and perspectives           
We have presented solid evidence that pre-existing and/or 
overexpressed iNOS/NO can compromise a widely used 
anti-cancer therapy, PDT, and possibly stimulate disease 
progression if the extent of tumor eradication is not great 
enough. Sensitizer or pro-sensitizer uptake by cells in a given 
tumor is not expected to be uniform throughout, nor is light 
delivery during PDT. As a result, some cells will be more 
heavily stressed by PDT than others, some of which might be 
relatively unaffected bystanders. Using in vitro model 
systems, we have shown that photostressed target cells 
induce iNOS/NO for survival/expansion and that this is also 
elicited in bystander cells via diffusible NO [39]. It appears 
that a “relay-type” system is established whereby NO 
initially produced by targeted cells induces iNOS/NO in a 
bystander cell and that this is propagated through the 
bystander population. Similar propagation may occur in the 
targeted population. However, it was only through evaluation 
of separated cell populations that this phenomenon came to 
be realized in our studies. In the genre of radiation biology, 
this process has been described as a NO “feed-forward field 
effect” [34]. As anticipated for target cells that survive PDT, 
enhanced proliferative and migratory aggressiveness of 
bystander cells could potentially promote tumor growth and 
metastatic expansion. These negative side effects could be 
minimized through rational pharmacologic use of iNOS 
inhibitors as PDT adjuvants. Two promising candidates in 
this regard are L-NIL and GW274150, which have already 
been safely tested in clinical trials not related to cancer or 
PDT [41, 42]. 
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